Today's Peptide News — August 21, 2026

A bioRxiv preprint describes a computational, structure-guided pipeline that designs peptide-based inhibitors against secreted peptidases of the fungal pathogen Cryptococcus. The team targeted three virulence-associated enzymes — Rim13, May1, and CnMpr1 — that the fungus uses to establish infection and evade host defenses. Rather than screening large physical libraries, the pipeline used enzyme structures to guide inhibitor design, then validated the candidates in cell-based assays.

The designed peptides suppressed peptidase-driven virulence and, importantly, showed additive activity when combined with the antifungal drug fluconazole while producing no measurable toxicity to host cells. That combination hints at a way to blunt drug resistance by attacking the pathogen's virulence machinery alongside conventional antifungals.

Fungal infections are a growing and under-treated threat, and the pipeline is a template that could be redirected at other pathogens' proteases. For PeptideWiki, a strong short post would explain how structure-guided peptide design differs from library screening, and why hitting a pathogen's virulence enzymes — rather than its growth directly — is an attractive strategy for slowing resistance.

Researchers combining laboratory experiments with molecular simulation report new mechanistic detail on how antimicrobial peptides breach bacterial membranes. The work found that peptides coating the outside of a cell can flip across the membrane, and that this translocation is central to pore formation. Peptides that disrupt the membrane more dramatically tend to form larger pores that stay open longer, killing the cell more effectively.

The finding matters because antimicrobial peptides are one of the more promising alternatives to conventional antibiotics against drug-resistant bacteria, but designing potent, selective versions has been hard without a clear picture of what separates a strong pore-former from a weak one. Tying killing power to a measurable physical behavior — membrane translocation and pore stability — gives designers a concrete property to optimize.

For a PeptideWiki post, the natural angle is a plain-language explainer of how antimicrobial peptides kill by making holes in membranes, using this study to show why the "flip" step is the difference between a peptide that merely sticks to a cell and one that destroys it.

A Nature Reviews Methods Primers article lays out the current toolkit for discovering peptide ligands that act on G protein-coupled receptors, the largest single class of drug targets in the human genome. Peptides are an increasingly important ligand type for GPCRs because they can achieve high affinity and selectivity for receptors that small molecules struggle to engage well.

The review surveys computational design, library-based screening platforms, and biosensor assays for measuring how peptides activate receptors, alongside stabilization strategies — such as cyclization and backbone modification — that address the short half-lives and poor oral availability that have historically limited peptide drugs. Taken together, these approaches are what make modern peptide GPCR drugs, including the GLP-1 receptor agonists, practical medicines.

Because GLP-1 drugs are themselves GPCR-targeting peptides, this review is a useful backbone for a PeptideWiki explainer connecting the science of peptide-GPCR discovery to the blockbuster obesity and diabetes drugs readers already know.

A randomized, double-blind, placebo-controlled Phase 2 trial published in Nature Medicine reports that aleniglipron, an orally dosed small-molecule GLP-1 receptor agonist, helped adults with obesity or overweight lose as much as 12 percent of their body weight over 36 weeks. The study enrolled 230 adults with an average age of 50 across 38 US sites and focused on safety alongside weight outcomes.

Unlike semaglutide and tirzepatide, which are injectable peptides, aleniglipron is a small molecule designed to hit the same GLP-1 receptor in pill form. Oral options that approach injectable-level efficacy would substantially widen access to this drug class by removing the barriers of injections and cold-chain storage.

The obvious PeptideWiki angle is a compare-and-contrast piece: what a peptide GLP-1 agonist and a small-molecule GLP-1 agonist share, where they differ pharmacologically, and why the field is racing to put GLP-1 activity into a daily pill.

At the 2026 American Diabetes Association Scientific Sessions, Phase 3 results for retatrutide were presented from the TRIUMPH-1 trial in adults with obesity without type 2 diabetes and TRANSCEND-T2D-1 in adults with type 2 diabetes. Retatrutide is a triple agonist that activates the GIP, GLP-1, and glucagon receptors, one step beyond the dual GIP/GLP-1 mechanism of tirzepatide.

In TRIUMPH-1, retatrutide produced weight loss above 28 percent — the highest yet reported from a Phase 3 obesity trial — pushing the ceiling of what injectable incretin therapies can achieve and moving the drug closer to a regulatory filing.

For PeptideWiki, retatrutide is a chance to explain the logic of adding glucagon-receptor agonism to the incretin mix and why "triple agonist" peptides are the current frontier of obesity pharmacology.

An AJMC overview describes how the GLP-1 drug class in 2026 is being studied and used for far more than diabetes and weight loss. Trials and real-world data now point toward benefits and active investigation in cardiovascular disease, kidney disease, sleep apnea, liver disease, and even neurodegenerative and addiction-related conditions.

The expansion reflects a shift in how these peptide drugs are understood: from glucose-lowering agents to broad metabolic and anti-inflammatory therapies whose effects reach multiple organ systems. That breadth is reshaping clinical guidelines and driving enormous demand.

A PeptideWiki post could catalog the expanding indications for GLP-1 peptides and explain, mechanistically, why a single receptor pathway ends up touching so many different diseases.

New research reported this week suggests that semaglutide, sold as Ozempic and Wegovy, may act in the brain in almost the reverse of what researchers had assumed. Rather than simply suppressing appetite circuits, the drug appears to activate certain hunger-linked neurons that turn out to be essential for sustaining fat loss over time.

The counterintuitive finding complicates the simple story that GLP-1 drugs work purely by dialing down hunger, and it could help explain why weight often returns when people stop taking them. Understanding which neural circuits are truly required to maintain fat loss may guide better combination therapies and dosing strategies.

Because this is a mechanism story about a peptide drug, it is a natural PeptideWiki item — a short explainer on how GLP-1 signaling in the brain governs body weight, and why the biology is proving more surprising than expected.

A new genetics study found that more than 1,000 regulatory switches in the genome behave differently in male versus female immune cells. These sex-specific differences in gene regulation help explain why women are far more susceptible to autoimmune diseases such as lupus, which strike women several times more often than men.

The work moves beyond describing that autoimmune risk differs by sex to pointing at concrete molecular machinery behind the gap, which could eventually inform sex-aware approaches to diagnosis and treatment.

This is a general science and health item, included for context in the daily digest rather than as PeptideWiki post material.

Using specialized brain imaging, researchers report that schizophrenia is associated with a widespread loss of synapses, the connections between neurons, with the left hemisphere appearing especially affected. The findings support the idea that the disorder involves large-scale disruption of brain connectivity rather than a defect confined to a single region.

Being able to visualize synaptic loss in living patients could improve understanding of the disease and offer a way to track it or test whether treatments preserve connections.

This item is included as general science news for the digest and is not intended as PeptideWiki post material.